Thinking twice before abandoning first-line chemotherapy in ovarian cancer: Report of two cases and literature review. Passing from tri-weekly to weekly regimens

Claudia Marchetti, Filippo Bellati, Angela Musella, Chiara Napoletano, Giorgia Perniola, Violante Di Donato, Sandro Pignata, Marianna Nuti, Pierluigi Benedetti Panici

Research output: Contribution to journalArticlepeer-review

Abstract

We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel. Therapy was converted to weekly regimens because of disease progression, resulting in disease response. Weekly regimens could overcome drug resistance and this strategy should be attempted before abandoning first-line chemotherapy in favor of palliation.

Original languageEnglish
Pages (from-to)385-389
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - Aug 2012

Keywords

  • Carboplatin
  • Ovarian cancer
  • Weekly paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Fingerprint Dive into the research topics of 'Thinking twice before abandoning first-line chemotherapy in ovarian cancer: Report of two cases and literature review. Passing from tri-weekly to weekly regimens'. Together they form a unique fingerprint.

Cite this